InVivo Therapeutics Holdings Corp., focused on polymer technology to develop treatments to improve function in individuals with spinal cord injury, today announced former Stryker biomaterials product development specialist Brian Hess as its director of product development.
In the role of director, Hess is responsible for the management, development, and maintenance of InVivo's pipeline and portfolio of products. Hess will head the effort to transition InVivo technologies from research and development through clinical trials and into production manufacturing by developing specifications, protocols, and reports.
Hess' most previous role was his eight-year tenure with Stryker, where he developed biomaterial technologies for the orthopedic market. He has led multiple product development teams through the FDA process, and was instrumental in developing HydroSetTM, an injectable calcium phosphate based bone substitute, from concept to product launch. HydroSet has become the market-leading bone scaffold, and in recognition of his success, Stryker awarded Hess and his team with "Best Technology" and "Best Team Synergy."
Hess' resume also includes the achievement of being named "Co-Innovator of the Year" in 2010 at Stryker for his work on a novel bone adhesive technology. Hess and his team spent the past three years demonstrating the technology's feasibility and safety, growing his team to more than 25 engineers and scientists.
"We believe Brian's past successes in the medical device industry will lead the commercialization of the three products we intend to have under review at FDA this year, as well as help to bring our portfolio of products for other neurological conditions successfully to the market in the coming years," InVivo CEO Frank Reynolds stated in the press release.
For more information visit invivotherapeutics.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net